Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122943 | 0.76 | L3MBTL1 (0.49) | L3MBTL1KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL12768178 | 0.72 | SMN1; SMN2 (0.48) | L3MBTL1KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL12256527 | 0.71 | NPC1 (0.55) | L3MBTL1KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL20353287 | 0.70 | KDM4E (0.56) | L3MBTL1KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL11842728 | 0.69 | KDM4E (0.55) | L3MBTL1KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL6344078 | 0.67 | KDM4E (0.52) | L3MBTL1KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL23913951 | 0.67 | L3MBTL1 (0.41) | L3MBTL1KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL23264897 | 0.67 | NPC1 (0.44) | L3MBTL1KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL23245313 | 0.66 | L3MBTL1 (0.38) | L3MBTL1KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL23245312 | 0.66 | L3MBTL1 (0.38) | L3MBTL1KDM4ENPC1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319698-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11560385-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3814338-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Proteostasis Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-04-22 | — | — | US | disclosed |
| CN-112585132-A | Proteasome activity enhancing compounds | 蛋白质平衡治疗股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | L3MBTL1 2593/4885KDM4E 1276/4885NPC1 675/4885 |
| US-11560385-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | L3MBTL1 2593/4885KDM4E 1276/4885NPC1 675/4885 |
| US-12319698-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | L3MBTL1 2593/4885KDM4E 1276/4885NPC1 675/4885 |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | L3MBTL1 2593/4885KDM4E 1276/4885NPC1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.